Puma Biotechnology (PBYI) Stock Price, News & Analysis

Company Overview

Puma Biotechnology, Inc. is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer. Nerlynx has since been explored in additional settings, including metastatic disease, reflecting Puma’s commitment to expanding therapeutic options for patients.

Beyond its approved product, Puma Biotechnology maintains a clinical‐stage pipeline that includes additional oncology candidates and combination regimens under evaluation in multiple cancer indications. Through ongoing trials, the company aims to build on Nerlynx’s platform and bring new treatment options to patients facing aggressive tumors.

Since completing its initial public offering on Nasdaq under the ticker PBYI in 2013, Puma has established commercial operations in the United States and forged partnerships to support product launches and regulatory filings in Europe and other global markets. Under the leadership of Founder and President/CEO Alan H. Auerbach, the company continues to leverage strategic collaborations and scientific expertise to drive its growth and development efforts.

Key Stats

• Today's Range: $7.40 to $7.70
• 50-Day Range: $5.70 to $7.80
• 52-Week Range: $2.85 to $7.90
• Volume: 484,456 shs
• Average Volume: 373,980 shs
• Market Capitalization: $379.13 million
• P/E Ratio: 12.21
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Puma Biotechnology Stock Analysis - MarketRank™

Puma Biotechnology scored higher than 22% of companies evaluated by MarketBeat, and ranked 764th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Puma Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Puma Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 142.86%

Earnings Growth

Earnings for Puma Biotechnology are expected to grow by 142.86% in the coming year, from $0.14 to $0.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Puma Biotechnology is 12.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.48.

Price to Earnings Ratio vs. Sector

The P/E ratio of Puma Biotechnology is 12.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.30.

Price to Book Value per Share Ratio

Puma Biotechnology has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.65% of the float of Puma Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Puma Biotechnology has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Puma Biotechnology has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Puma Biotechnology does not currently pay a dividend.

Dividend Growth

Puma Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Puma Biotechnology this week, compared to 1 article on an average week.

Search Interest

2 people have searched for PBYI on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Puma Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.30% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PBYI Stock Analysis - Frequently Asked Questions

How have PBYI shares performed this year?

Puma Biotechnology's stock was trading at $5.95 at the start of the year. Since then, PBYI stock has increased by 25.2% and is now trading at $7.45.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. The biopharmaceutical company had revenue of $75.50 million for the quarter, compared to the consensus estimate of $68.60 million. Puma Biotechnology had a trailing twelve-month return on equity of 27.80% and a net margin of 13.62%.
Read the conference call transcript.

Who are Puma Biotechnology's major shareholders?

Top institutional investors of Puma Biotechnology include Ritholtz Wealth Management (1.52%), Bank of New York Mellon Corp (0.68%), Strs Ohio (0.18%) and Baron Wealth Management LLC (0.08%). Insiders that own company stock include Alan H Auerbach, Maximo F Nougues, Douglas M Hunt, Jeffrey Jerome Ludwig, Alvin F Wong, Brian M Stuglik, Allison Dorval, Michael Patrick Miller, Jay M Moyes, Troy Edward Wilson, Alessandra Cesano and Adrian Senderowicz.
View institutional ownership trends.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBYI
• CIK: 1401667
• Web: www.pumabiotechnology.com
• Phone: (424) 248-6500
• Fax: 424-248-6501
• Employees: 200
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): $0.61
• Trailing P/E Ratio: 12.21
• Forward P/E Ratio: 53.21
• P/E Growth: N/A
• Net Income: $31.11 million
• Net Margins: 13.62%
• Pretax Margin: 15.67%
• Return on Equity: 27.80%
• Return on Assets: 15.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.00
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $228.40 million
• Price / Sales: 1.66
• Cash Flow: $0.83 per share
• Price / Cash Flow: 9.03
• Book Value: $2.59 per share
• Price / Book: 2.88

Miscellaneous

• Outstanding Shares: 50,890,000
• Free Float: 39,034,000
• Market Cap: $379.13 million
• Optionable: Optionable
• Beta: 1.24